Literature DB >> 26555080

Absence of mutations in HCRT, HCRTR1 and HCRTR2 in patients with ROHHAD.

Sarah F Barclay1, Casey M Rand2, Paul A Gray3, William T Gibson4, Richard J A Wilson5, Elizabeth M Berry-Kravis6, Diego Ize-Ludlow7, N Torben Bech-Hansen8, Debra E Weese-Mayer9.   

Abstract

BACKGROUND AND OBJECTIVES: Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) is a rare pediatric disease of unknown cause. Here, in response to a recent case report describing a ROHHAD patient who suffered from secondary narcolepsy confirmed by an absence of hypocretin-1 in the cerebrospinal fluid, we consider whether the ROHHAD phenotype is owing to one or more mutations in genes specific to hypocretin protein signalling.
METHODS: DNA samples from 16 ROHHAD patients were analyzed using a combination of next-generation and Sanger sequencing to identify exonic sequence variations in three genes: HCRT, HCRTR1, and HCRTR2.
RESULTS: No rare or novel mutations were identified in the exons of HCRT, HCRTR1, or HCRTR2 genes in a set of 16 ROHHAD patients.
CONCLUSIONS: ROHHAD is highly unlikely to be caused by mutations in the exons of the genes for hypocretin and its two receptors.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autonomic dysregulation; Exome sequencing; Genes; HCRT; HCRTR1; HCRTR2; Hyothalamic dysfunction; Hypocretin; Hypoventilation; Mutations; Narcolepsy; Next-generation sequencing; Obesity; Orexin; ROHHAD

Mesh:

Substances:

Year:  2015        PMID: 26555080     DOI: 10.1016/j.resp.2015.11.002

Source DB:  PubMed          Journal:  Respir Physiol Neurobiol        ISSN: 1569-9048            Impact factor:   1.931


  6 in total

Review 1.  Genetic and Syndromic Causes of Obesity and its Management.

Authors:  Ildiko H Koves; Christian Roth
Journal:  Indian J Pediatr       Date:  2017-11-27       Impact factor: 1.967

2.  Evolution of physiologic and autonomic phenotype in rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation over a decade from age at diagnosis.

Authors:  Ilya Khaytin; Tracey M Stewart; Frank A Zelko; Mitsu A L Kee; Jennifer N Osipoff; Susan M Slattery; Debra E Weese-Mayer
Journal:  J Clin Sleep Med       Date:  2022-03-01       Impact factor: 4.062

3.  Rapid-Onset Obesity with Hypoventilation, Hypothalamic, Autonomic Dysregulation, and Neuroendocrine Tumors (ROHHADNET) Syndrome: A Systematic Review.

Authors:  Jiwon M Lee; Jaewon Shin; Sol Kim; Heon Yung Gee; Joon Suk Lee; Do Hyeon Cha; John Hoon Rim; Se-Jin Park; Ji Hong Kim; Ahmet Uçar; Andreas Kronbichler; Keum Hwa Lee; Jae Il Shin
Journal:  Biomed Res Int       Date:  2018-11-21       Impact factor: 3.411

4.  Case Report: COVID-19-Associated ROHHAD-Like Syndrome.

Authors:  Irina N Artamonova; Natalia A Petrova; Natalia A Lyubimova; Natalia Yu Kolbina; Alexander V Bryzzhin; Alexander V Borodin; Tatyana A Levko; Ekaterina A Mamaeva; Tatiana M Pervunina; Elena S Vasichkina; Irina L Nikitina; Anna M Zlotina; Alexander Yu Efimtsev; Mikhail M Kostik
Journal:  Front Pediatr       Date:  2022-03-31       Impact factor: 3.418

5.  ZSCAN1 Autoantibodies Are Associated with Pediatric Paraneoplastic ROHHAD.

Authors:  Caleigh Mandel-Brehm; Leslie A Benson; Baouyen Tran; Mark P Gorman; Joseph L DeRisi; Andrew F Kung; Sabrina A Mann; Sara E Vazquez; Hanna Retallack; Hannah A Sample; Kelsey C Zorn; Lillian M Khan; Lauren M Kerr; Patrick L McAlpine; Lichao Zhang; Frank McCarthy; Joshua E Elias; Umakanth Katwa; Christina M Astley; Stuart Tomko; Josep Dalmau; William W Seeley; Samuel J Pleasure; Michael R Wilson
Journal:  Ann Neurol       Date:  2022-05-25       Impact factor: 11.274

6.  ROHHAD syndrome without rapid-onset obesity: A diagnosis challenge.

Authors:  Blandine Desse; Antoine Tran; Mathilde Butori; Sarah Marchal; Michael Afanetti; Sébastien Barthélemy; Etienne Bérard; Elisabeth Baechler; Stéphane Debelleix; Marie-Emilie Lampin; Julie Macey; Bruno Massenavette; Julie Harvengt; Ha Trang; Lisa Giovannini-Chami
Journal:  Front Pediatr       Date:  2022-08-31       Impact factor: 3.569

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.